1. Phenylketonuria (PKU) Market DelveInsight's "Phenylketonuria (PKU) - Market Insights, Epidemiology, and Market Forecast- 2030" report delivers an in-depth understanding of the Phenylketonuria (PKU), historical and forecasted epidemiology as well as the Phenylketonuria (PKU) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Phenylketonuria (PKU) market report provides current treatment practices, emerging drugs, Phenylketonuria (PKU) market share of the individual therapies, current and forecasted Phenylketonuria (PKU) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Phenylketonuria (PKU) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geography Covered    The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period:2017-2030 Phenylketonuria (PKU) Disease Understanding and Treatment Algorithm The DelveInsight Phenylketonuria (PKU) market report gives a thorough understanding of the Phenylketonuria (PKU) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

2. Request request/phenylketonuria-pku-market Phenylketonuria (PKU) Epidemiology Different forms of PKU with different clinical phenotypes have been described depending on the enzyme defect, the genotype, and the severity of the disease, establishing different classifications for PKU phenotypes. PKU may be classified as classic PKU and as variant PKU, which includes all milder forms of PKU (i.e., moderate PKU and mild PKU), as mild hyperphenylalaninemia (HPA) or non-PKU HPA, and, additionally, as BH4-responsive PKU. The Phenylketonuria (PKU) epidemiology division provide insights about historical and current Phenylketonuria (PKU)patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key Findings The disease epidemiology covered in the report provides historical as well as forecasted Phenylketonuria (PKU)epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. Country Wise- Phenylketonuria (PKU) Epidemiology The epidemiology segment also provides the Phenylketonuria (PKU) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Phenylketonuria (PKU) Drug Chapters Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Synlogic, Censa Pharmaceuticals, Codexis, Homology Medicines, etc., are developing therapies for the treatment of patients with Phenylketonuria (PKU). Drug chapter segment of the Phenylketonuria (PKU) report encloses the detailed analysis of Phenylketonuria (PKU) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Phenylketonuria (PKU)clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Marketed Drugs The report provides the details of the marketed product available for Phenylketonuria (PKU) treatment. Phenylketonuria (PKU) Emerging Drugs The report provides the details of the emerging therapies under the late and mid-stage of development for Phenylketonuria (PKU) treatment. Request for sample pages: https://www.delveinsight.com/sample- request/phenylketonuria-pku-market Phenylketonuria (PKU) Market Outlook Currently, there is no cure for Phenylketonuria (PKU); however, the prevailing treatment is predominantly through dietary restriction of phenylalanine (Phe) to the minimum required for normal for sample pages: https://www.delveinsight.com/sample-

3. growth, supplemented with specifically designed medical foods. For many years, the only treatment for PKU has been the adherence to this strict low phenylalanine diet for life. Therefore, the first line of therapy for PKU treatment is dietary therapy, where a low Phe diet is supplemented with amino acid formulas, which commences soon after diagnosis. The goal of treatment for PKU is to keep plasma phenylalanine levels within 120–360 µmol/L (2–6 mg/dL), which is achieved through carefully planned and monitored diet. Limiting the child’s intake of phenylalanine, cautiously as it is an essential amino acid. A carefully maintained diet can prevent intellectual disability as well as neurological, behavioral, and dermatological problems. Although dietary treatment has been successful in preventing intellectual disability in the early treated PKU patients, there are major issues with dietary compliance due to the palatability of the diet. The Phenylketonuria (PKU) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Phenylketonuria (PKU)markettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Phenylketonuria (PKU) market in 7MM is expected to change in the study period 2017-2030. View full report: https://www.delveinsight.com/report-store/phenylketonuria-pku-market Download request/phenylketonuria-pku-market sample pages: https://www.delveinsight.com/sample-